Combination Therapeutic Nanoparticle Platform Drug Delivery System
- *Abstract
-
Applications
Prostatecancer is one of the most frequently diagnosed and deadly forms of canceraffecting men in the United States and around the world. Nanotechnology has recently emerged as apromising method for the delivery of multiple drugs with high efficiency. Nanoparticles based on the Food and DrugAdministration (FDA) approved polymers such as poly(lactide-co-glycolide)(PLGA) and poly(ethyleneglycol) (PEG) have shown exceptional ability to entertumor tissues through enhanced permeability and retention effect and releasetherapeutics in a controlled fashion.
Withthis in mind, UGA researchers have designed a controlled-release, highlyfunctionalized nanoparticle platform drug delivery system with the capabilitiesto deliver synergistic combinations of chemotherapeutics, anti-inflammatoryagents, and bone resorption inhibitors. These nanoparticles can be used for the treatment of cancers, including oneof the deadliest forms of cancer, castration-resistant prostate cancer (CRPC). This technology:
· Cancombine two or more cancer therapeutics, with the potential to lead to enhancedpatient outcome
· Controlledspatio-temporal release of different therapeutics, resulting in more targeteddelivery and reduced toxicity
· Applicableto a wide range of cancer types
ProblemsAddressed
· Virtuallyendless number of possible therapeutic combinations for cancer and beyond
· Allowsthe delivery of controlled stoichiometric ratios of therapeutics withoutaffecting the biocompatibility of the polymeric system
· Spatio-temporalrelease of different therapeutics allows a customized dosing regimen
TechnologySummary
Thetechnology is a combined nanoparticle system with both anti-inflammatory andchemotherapeutic properties. Theadvantage ofthis technology over others is that the anti-inflammatory and chemotherapeuticcomponents are encapsulated separately and then covalently linked. This allows customized doses of each of thesecomponents for combined therapeutic applications.
Inventors
• ShantaDhar, Assistant Professor of Chemistry
• RakeshPathak, Post-doctoral Fellow
TechnologyDevelopment and IP Status
· Invitro proof-of-concept data generated for prostate cancer cell lines;
· PCTapplication published: PCT/US2014/033431
- Country/Region
- USA
